HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DUALITYBIO-B

191.700

-2.800-1.44%

Volume:486.72K

Turnover:94.84M

Market Cap:17.41B

PE:-4.82

High:202.400

Open:195.000

Low:190.000

Close:194.500

52wk High:563.500

52wk Low:158.500

Shares:90.82M

HK Float Shares:90.82M

Volume Ratio:1.28

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-39.800

ROE:-1282.14%

ROA:-9.61%

PB:6.15

PE(LYR):-4.82

PS:8.06

Loading ...

Overview Company News Filings

DUALITYBIO-B (09606) Announces Dr. Hua Haiqing Appointed as Executive Director

Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000

Duality Biotherapeutics reports DB-1303 Phase 3 trial meets primary PFS endpoint

Duality Biotherapeutics - Loss for Year Attributable RMB2.59 Bln

THOMSON REUTERS

Duality Biotherapeutics Inc - Si Wen Tendered Resignation as Executive Director

THOMSON REUTERS

Duality Biotherapeutics appoints HUA Haiqing as executive director and names ZHANG Shaoren CFO

Duality Biotherapeutics Inc - Zhang Shaoren Has Been Appointed as CFO

THOMSON REUTERS

HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.

Tiger Newspress

DUALITYBIO-B (09606) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results and Review Final Dividend Proposal

Bulletin Express

Duality Biotherapeutics to Hold Board Meeting on Annual Results and Final Dividend Proposal

Prospective Adjustments to Hong Kong Stock Connect in March: 44 Stocks Poised for Inclusion, Featuring Insilico (03696) and JD Industrials (07618)

Duality Biotherapeutics (09606) Announces February 2026 Monthly Return on Securities Movements

Bulletin Express

Duality Biotherapeutics Says DB-1311 Shows Signs of Activity in Early-Stage Prostate Cancer Study

MT Newswires Live

Duality Biotherapeutics, Inc. (9606) Presents DB-1311/BNT324 Study Updates at ASCO GU Cancers Symposium 2026

Bulletin Express

DUALITYBIO-B Announces Phase 1/2 Trial Results for DB-1311/BNT324 at 2026 ASCO GU Symposium

Duality Biotherapeutics to Present Updated DB-1311/BNT324 Phase 1/2 mCRPC Data at ASCO GU 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/09606/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"DUALITYBIO-B","latestPrice":191.7,"timestamp":1787542692751,"preClose":194.5,"halted":0,"volume":486716,"delay":0,"changeRate":-0.014395886889460212,"floatShares":90824200,"shares":90824200,"eps":-39.8,"marketStatus":"Trading","change":-2.8,"latestTime":"08-24 11:38:48","open":195,"high":202.4,"low":190,"amount":94838033,"amplitude":0.063753,"askPrice":191.7,"askSize":300,"bidPrice":191.4,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-31.631,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1787544000000},"marketStatusCode":2,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":194.5,"openAndCloseTimeList":[[1787535000000,1787544000000],[1787547600000,1787558400000]],"volumeRatio":1.284281,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","floatShares":90824200,"roa":"-9.61%","roe":"-1282.14%","lyrEps":-39.8,"volumeRatio":1.284281,"shares":90824200,"dividePrice":0,"high":202.4,"amplitude":0.063753,"preClose":194.5,"low":190,"week52Low":158.5,"pbRate":"6.15","psRate":"8.06","week52High":563.5,"institutionHeld":0,"latestPrice":191.7,"committee":-0.5,"eps":-39.8,"divideRate":0,"volume":486716,"delay":0,"ttmEps":-31.631,"open":195,"prevYearClose":298.2,"prevWeekClose":194.5,"prevMonthClose":181.8,"prevQuarterClose":181.2,"fiveDayClose":186,"twentyDayClose":227.4,"sixtyDayClose":209.2,"earningDate":1787846400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09606\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-23","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774229400000,"name":null,"time":"","dateTimestamp":1774195200000,"actualEps":null},{"date":"2025-08-26","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09606\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09606\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1783440000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09606\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09606","date":"2026-08-21","current":-6.149031,"percent":0.906627,"low":-29.984477,"twenty":-16.354018,"median":-9.310353,"eighty":-6.918832,"high":-4.703556,"avg":-11.684236,"sd":6.231586,"marketCap":17593072323},"quantilePoints":[{"date":"2025-04-17","current":-14.905978,"twenty":-15.065639,"median":-14.442293,"eighty":-11.334487,"marketCap":16635152800},{"date":"2025-04-25","current":-15.846935,"twenty":-16.770434,"median":-15.576033,"eighty":-14.349556,"marketCap":17719522633},{"date":"2025-05-02","current":-16.438538,"twenty":-16.715855,"median":-16.124153,"eighty":-14.985809,"marketCap":18420101638},{"date":"2025-05-09","current":-15.074661,"twenty":-16.551291,"median":-15.826729,"eighty":-15.074661,"marketCap":17010399982},{"date":"2025-05-16","current":-15.043786,"twenty":-16.438538,"median":-15.220044,"eighty":-14.405796,"marketCap":17114249721},{"date":"2025-05-23","current":-16.495727,"twenty":-16.438538,"median":-15.262587,"eighty":-14.582474,"marketCap":18822153243},{"date":"2025-05-30","current":-16.208434,"twenty":-16.401371,"median":-15.460562,"eighty":-14.726132,"marketCap":18575651704},{"date":"2025-06-06","current":-16.427701,"twenty":-16.438538,"median":-15.666395,"eighty":-14.905978,"marketCap":18874975001},{"date":"2025-06-13","current":-20.940103,"twenty":-16.693343,"median":-15.893657,"eighty":-15.005253,"marketCap":24069114577},{"date":"2025-06-20","current":-18.479443,"twenty":-18.428819,"median":-16.104695,"eighty":-15.043786,"marketCap":21199132371},{"date":"2025-06-27","current":-18.0452,"twenty":-18.863356,"median":-16.282988,"eighty":-15.074661,"marketCap":20758951051},{"date":"2025-07-04","current":-21.227749,"twenty":-18.942282,"median":-16.427701,"eighty":-15.074735,"marketCap":24421259633},{"date":"2025-07-11","current":-22.045806,"twenty":-19.683704,"median":-16.508309,"eighty":-15.190609,"marketCap":25336836779},{"date":"2025-07-18","current":-25.758166,"twenty":-20.839221,"median":-16.693343,"eighty":-15.21995,"marketCap":29580184704},{"date":"2025-07-25","current":-25.970367,"twenty":-21.539184,"median":-16.981252,"eighty":-15.260218,"marketCap":29932329760},{"date":"2025-08-01","current":-24.963588,"twenty":-22.267132,"median":-18.096065,"eighty":-15.298157,"marketCap":28594178547},{"date":"2025-08-08","current":-27.998627,"twenty":-24.402884,"median":-18.454131,"eighty":-15.429476,"marketCap":32150843612},{"date":"2025-08-15","current":-27.487815,"twenty":-25.397092,"median":-18.863356,"eighty":-15.513126,"marketCap":31516982512},{"date":"2025-08-22","current":-26.341915,"twenty":-25.761111,"median":-19.052333,"eighty":-15.750472,"marketCap":30108402288},{"date":"2025-08-29","current":-8.977182,"twenty":-25.761111,"median":-19.118727,"eighty":-15.513126,"marketCap":27784244918},{"date":"2025-09-05","current":-10.341403,"twenty":-25.547361,"median":-18.897362,"eighty":-15.21995,"marketCap":31974771084},{"date":"2025-09-12","current":-12.806892,"twenty":-25.484142,"median":-18.479443,"eighty":-15.036079,"marketCap":39669140558},{"date":"2025-09-19","current":-11.291493,"twenty":-25.397092,"median":-18.151913,"eighty":-14.569138,"marketCap":34950396808},{"date":"2025-09-26","current":-9.575685,"twenty":-25.265241,"median":-17.183112,"eighty":-14.242848,"marketCap":29562577451},{"date":"2025-10-03","current":-9.769092,"twenty":-25.225948,"median":-16.756996,"eighty":-13.467837,"marketCap":30231653057},{"date":"2025-10-10","current":-8.39875,"twenty":-25.201143,"median":-16.551291,"eighty":-12.508489,"marketCap":25953090627},{"date":"2025-10-17","current":-9.52866,"twenty":-25.090759,"median":-16.467132,"eighty":-11.127698,"marketCap":29421719428},{"date":"2025-10-24","current":-8.24833,"twenty":-24.683236,"median":-16.401371,"eighty":-10.383008,"marketCap":25477694801},{"date":"2025-10-31","current":-8.936138,"twenty":-24.228898,"median":-16.208434,"eighty":-10.01166,"marketCap":27643386896},{"date":"2025-11-07","current":-8.115895,"twenty":-24.0933,"median":-15.983588,"eighty":-9.661913,"marketCap":25090335240},{"date":"2025-11-14","current":-9.615008,"twenty":-24.036348,"median":-15.846935,"eighty":-9.533336,"marketCap":29809078990},{"date":"2025-11-21","current":-8.88084,"twenty":-23.659864,"median":-15.493415,"eighty":-9.411746,"marketCap":27520136126},{"date":"2025-11-28","current":-9.805814,"twenty":-23.032171,"median":-15.270261,"eighty":-9.358381,"marketCap":30496838785},{"date":"2025-12-05","current":-9.522579,"twenty":-22.810207,"median":-15.147164,"eighty":-9.358381,"marketCap":29666872704},{"date":"2025-12-12","current":-9.227769,"twenty":-22.078047,"median":-15.043786,"eighty":-9.232281,"marketCap":28801588916},{"date":"2025-12-19","current":-9.562517,"twenty":-22.024358,"median":-14.816055,"eighty":-9.195431,"marketCap":29916743432},{"date":"2025-12-24","current":-8.86445,"twenty":-21.960012,"median":-14.582474,"eighty":-9.185632,"marketCap":27819193982},{"date":"2026-01-02","current":-8.361415,"twenty":-21.780535,"median":-14.405796,"eighty":-9.071858,"marketCap":26343799029},{"date":"2026-01-09","current":-10.158481,"twenty":-21.573184,"median":-14.143758,"eighty":-9.138635,"marketCap":32085396254},{"date":"2026-01-16","current":-10.130227,"twenty":-21.338723,"median":-13.671075,"eighty":-9.159542,"marketCap":32100133626},{"date":"2026-01-23","current":-9.450777,"twenty":-21.128733,"median":-12.833558,"eighty":-9.159542,"marketCap":29918397524},{"date":"2026-01-30","current":-9.27281,"twenty":-20.989151,"median":-11.556174,"eighty":-9.159542,"marketCap":29489203537},{"date":"2026-02-06","current":-8.834279,"twenty":-20.864442,"median":-11.154997,"eighty":-9.026205,"marketCap":28165855410},{"date":"2026-02-13","current":-9.445101,"twenty":-20.730279,"median":-10.443288,"eighty":-9.076015,"marketCap":30286271904},{"date":"2026-02-20","current":-9.824687,"twenty":-20.674464,"median":-10.43817,"eighty":-9.09489,"marketCap":31458062186},{"date":"2026-02-27","current":-8.771359,"twenty":-20.006759,"median":-10.305855,"eighty":-9.047703,"marketCap":28393379910},{"date":"2026-03-06","current":-8.859488,"twenty":-19.896232,"median":-10.18539,"eighty":-8.969972,"marketCap":28447462538},{"date":"2026-03-13","current":-7.555838,"twenty":-19.630572,"median":-10.144354,"eighty":-8.935093,"marketCap":24373237865},{"date":"2026-03-20","current":-7.859442,"twenty":-19.432697,"median":-9.991099,"eighty":-8.867218,"marketCap":25256587462},{"date":"2026-03-27","current":-8.718949,"twenty":-19.118727,"median":-9.951719,"eighty":-8.854358,"marketCap":25617138318},{"date":"2026-04-02","current":-9.880216,"twenty":-19.012497,"median":-9.885599,"eighty":-8.850342,"marketCap":29168564250},{"date":"2026-04-10","current":-9.180446,"twenty":-18.964111,"median":-9.878849,"eighty":-8.85641,"marketCap":27311727342},{"date":"2026-04-17","current":-9.417233,"twenty":-18.904163,"median":-9.820225,"eighty":-8.842311,"marketCap":28027927148},{"date":"2026-04-24","current":-8.878352,"twenty":-18.860571,"median":-9.805814,"eighty":-8.846908,"marketCap":26425587896},{"date":"2026-04-30","current":-8.372511,"twenty":-18.781003,"median":-9.783435,"eighty":-8.82699,"marketCap":24926391864},{"date":"2026-05-08","current":-7.738947,"twenty":-18.469318,"median":-9.736996,"eighty":-8.785939,"marketCap":23120131584},{"date":"2026-05-15","current":-6.609967,"twenty":-18.384608,"median":-9.691452,"eighty":-8.751075,"marketCap":20699742808},{"date":"2026-05-22","current":-6.440114,"twenty":-18.185423,"median":-9.652725,"eighty":-8.708072,"marketCap":20121739519},{"date":"2026-05-29","current":-6.506712,"twenty":-18.096065,"median":-9.620334,"eighty":-8.669056,"marketCap":20400514838},{"date":"2026-06-05","current":-5.374082,"twenty":-18.0452,"median":-9.575685,"eighty":-8.511806,"marketCap":16873830092},{"date":"2026-06-12","current":-5.36331,"twenty":-17.183112,"median":-9.557279,"eighty":-8.481744,"marketCap":16828616185},{"date":"2026-06-18","current":-5.321722,"twenty":-16.860136,"median":-9.537613,"eighty":-8.412993,"marketCap":16738188371},{"date":"2026-06-26","current":-4.703556,"twenty":-16.761475,"median":-9.522579,"eighty":-8.375473,"marketCap":14721648119},{"date":"2026-07-03","current":-6.212828,"twenty":-16.718804,"median":-9.508222,"eighty":-8.310046,"marketCap":19460065572},{"date":"2026-07-10","current":-6.457487,"twenty":-16.608112,"median":-9.462457,"eighty":-8.218812,"marketCap":20201573647},{"date":"2026-07-17","current":-6.192643,"twenty":-16.533051,"median":-9.445101,"eighty":-8.097368,"marketCap":19441980010},{"date":"2026-07-24","current":-6.744145,"twenty":-16.505793,"median":-9.428231,"eighty":-7.995787,"marketCap":21178194038},{"date":"2026-07-31","current":-5.225281,"twenty":-16.472851,"median":-9.409879,"eighty":-7.856069,"marketCap":16439776585},{"date":"2026-08-07","current":-5.555188,"twenty":-16.434203,"median":-9.398864,"eighty":-7.73561,"marketCap":17511664790},{"date":"2026-08-14","current":-5.519506,"twenty":-16.417169,"median":-9.342917,"eighty":-7.473767,"marketCap":17421211976},{"date":"2026-08-21","current":-5.561665,"twenty":-16.354018,"median":-9.310353,"eighty":-6.918832,"marketCap":17593072323}],"updateTime":1787508435586},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09606\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1108032269","title":"DUALITYBIO-B (09606) Announces Dr. Hua Haiqing Appointed as Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1108032269","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108032269?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:38","pubTimestamp":1774269511,"startTime":"0","endTime":"0","summary":"Effective March 23, 2026: (1) Ms. Si Wen has resigned from her positions as an executive director and a member of the remuneration committee; (2) Dr. Hua Haiqing has been appointed as an executive...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","LU2543165471.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621705941","title":"Duality Biotherapeutics FY2025 loss attributable to owners widened 146.99% to RMB 2,594,827,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2621705941","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621705941?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:38","pubTimestamp":1774269495,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics published an annual results announcement reporting FY 2025 revenue of RMB 1.9 billion, down 4.61%.FY 2025 loss for the year was RMB 2.6 billion and adjusted loss for the year was RMB 388.8 million, more than doubled.FY 2025 R&D expenses were RMB 837.8 million, up 0.12%.Cash and bank balances were RMB 3.3 billion as of Dec. 31, 2025, up 131.55%.Pipeline updates included a Phase 3 China trial of trastuzumab pamirtecan  meeting its primary endpoint of PFS versus T-DM1, and DB-1310 receiving two FDA Fast Track designations in 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLbdzsV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","BK1161","HK0000500386.USD","LU2543165471.USD","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621070594","title":"Duality Biotherapeutics reports DB-1303 Phase 3 trial meets primary PFS endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2621070594","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621070594?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:38","pubTimestamp":1774269487,"startTime":"0","endTime":"0","summary":"Duality reported progress across its antibody-drug conjugate portfolio, including 10 clinical-stage programs that have enrolled more than 3,200 patients globally.In breast cancer, the company said DB-1303 met a primary endpoint in a Phase 3 study versus T-DM1, supporting a potential path toward expanded use in later-line HER2+ disease.For prostate cancer, updated DB-1311 data in 146 heavily pretreated mCRPC patients showed a median rPFS of 11.3 months and a median OS of 22.5 months, positioning the asset for a planned global Phase 3 trial starting in 2026.In lung and breast cancer settings, Duality said DB-1310 received two FDA fast track designations, which could shorten development timelines and broaden partnering options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL3RdLMn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","09606","HK0000252152.HKD","LU2543165471.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621954705","title":"Duality Biotherapeutics - Loss for Year Attributable RMB2.59 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621954705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621954705?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:37","pubTimestamp":1774269478,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B09R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000500386.USD","BK1161","LU2543165471.USD","09606","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063703","title":"Duality Biotherapeutics Inc -  Si Wen Tendered Resignation as Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063703","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063703?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:25","pubTimestamp":1774268729,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0S7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000500386.USD","09606","HK0000252160.HKD","HK0000252152.HKD","BK1161","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621703004","title":"Duality Biotherapeutics appoints HUA Haiqing as executive director and names ZHANG Shaoren CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703004","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703004?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:25","pubTimestamp":1774268718,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics said executive director Wen Si resigned from the board and the remuneration committee for personal career development reasons, and will continue as executive director of human resources.Haiqing Hua was appointed an executive director after serving at the company as senior vice president and head of drug discovery, having joined in July 2021 as vice president and head of drug discovery.Hua previously held drug discovery and development roles including principal scientist at Lilly China R&D and work at Shanghai Hansoh BioMedical.Shaoren Zhang was appointed chief financial officer and is currently an executive director and vice president of finance, responsible for the group’s financial strategy, corporate finance, and capital management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL1R9wLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000500386.USD","BK1161","09606","HK0000252160.HKD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621703066","title":"Duality Biotherapeutics Inc -  Zhang Shaoren Has Been Appointed as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703066","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703066?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:25","pubTimestamp":1774268712,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0S6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2543165471.USD","09606","BK1161","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156982969","title":"HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1156982969","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156982969?lang=en_us&edition=fundamental","pubTime":"2026-03-17 10:41","pubTimestamp":1773715275,"startTime":"0","endTime":"0","summary":"Biotech stocks jumped in Hong Kong. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759","09688","02268","09966","01672","02359","06606","06978","02137","09995","02269","03347","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190504580","title":"DUALITYBIO-B (09606) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results and Review Final Dividend Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=1190504580","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190504580?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:43","pubTimestamp":1773218620,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics, Inc. (stock code: 09606, abbreviation: DUALITYBIO-B) has scheduled a board meeting for 23 March 2026. According to the company’s announcement, directors will consider and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618912338","title":"Duality Biotherapeutics to Hold Board Meeting on Annual Results and Final Dividend Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2618912338","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618912338?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:31","pubTimestamp":1773217911,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics will hold a board meeting on March 23, 2026 to consider and approve its annual results for the year ended Dec. 31, 2025. The board will also consider a recommendation on the payment of a final dividend.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL28J91w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","BK1161","LU2543165471.USD","HK0000500386.USD","HK0000252160.HKD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179855228","title":"Prospective Adjustments to Hong Kong Stock Connect in March: 44 Stocks Poised for Inclusion, Featuring Insilico (03696) and JD Industrials (07618)","url":"https://stock-news.laohu8.com/highlight/detail?id=1179855228","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179855228?lang=en_us&edition=fundamental","pubTime":"2026-03-06 14:32","pubTimestamp":1772778725,"startTime":"0","endTime":"0","summary":"According to the quarterly review results announced by Hang Seng Indexes Company on February 13, the adjustments will officially take effect starting March 9 (next Monday). Following the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","BK1231","02609","BK1160","03696","BKEAY","03660","BK1175","QFIN","02788","02617","01384","00659","02007","BK4588","NWSGY","BK1141","02698","SG9999003461.SGD","07618","BK1230","02656","03887","BK1572","CTRYY","BK1170","BK4585","BK1117","00023","BK1207","BK1601","BK1124","00863"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109377962","title":"Duality Biotherapeutics (09606) Announces February 2026 Monthly Return on Securities Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1109377962","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109377962?lang=en_us&edition=fundamental","pubTime":"2026-03-02 16:50","pubTimestamp":1772441419,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics, Inc. reported no changes in its authorized or issued share capital for the month ended 28 February 2026. Authorized share capital remained at 200,000,000 ordinary shares,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613763897","title":"Duality Biotherapeutics Says DB-1311 Shows Signs of Activity in Early-Stage Prostate Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2613763897","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613763897?lang=en_us&edition=fundamental","pubTime":"2026-02-24 11:33","pubTimestamp":1771904032,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics (HKG:9606) said updated data from an early-stage study of DB-1311/BNT324 showed signs of activity in patients with advanced prostate cancer who had already received multiple pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000500386.USD","HK0000252152.HKD","BK4566","BK4585","BK1161","DB","LU2543165471.USD","SSI","09606","BK4118","BK4552","BK4588","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140530522","title":"Duality Biotherapeutics, Inc. (9606) Presents DB-1311/BNT324 Study Updates at ASCO GU Cancers Symposium 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1140530522","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140530522?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:23","pubTimestamp":1771885417,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics, Inc. (the “Company”) (Stock Code: 9606) announced updated results from a Phase 1/2 DB-1311-O-1001 study (NCT05914116) of DB-1311/BNT324, an investigational B7H3 antibody drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101379908","title":"DUALITYBIO-B Announces Phase 1/2 Trial Results for DB-1311/BNT324 at 2026 ASCO GU Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=1101379908","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101379908?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:10","pubTimestamp":1771884635,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) has announced that updated efficacy and safety results from the Phase 1/2 DB-1311-O-1001 study (NCT05914116) for its investigational B7H3 antibody-drug conjugate (ADC),...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252152.HKD","BK4566","BK4585","BK1161","DB","LU2543165471.USD","09606","BK4118","BK4552","BK4588","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613275840","title":"Duality Biotherapeutics to Present Updated DB-1311/BNT324 Phase 1/2 mCRPC Data at ASCO GU 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613275840","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613275840?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:03","pubTimestamp":1771884238,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics Inc. announced updated efficacy and safety results from its Phase 1/2 DB-1311-O-1001 study  evaluating DB-1311/BNT324, an investigational B7-H3 antibody-drug conjugate, in heavily pretreated metastatic castration-resistant prostate cancer. The company said the data will be presented at the ASCO Genitourinary Cancers Symposium 2026  and that the study abstract was published on the symposium website on February 23, 2026. As of the September 5, 2025 data cutoff, 104 patients had been treated; among 58 response-evaluable patients, confirmed objective response rate was 34.5% and disease control rate was 87.9%, with median radiographic progression-free survival of 11.3 months in 82 evaluable patients; outcomes were reported as similar in patients with and without prior lutetium-177 PSMA-617 treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL32V5N0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252152.HKD","09606","HK0000500386.USD","LU2543165471.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":7,"totalSize":136,"code":"91000000","status":"200"}]}}